Addex Therapeutics Ltd
Chemin des Mines 9,
CH-1202 Geneva, Switzerland
May 12, 2023 | Via Edgar |
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-3561
Attn: Alan Campbell
RE: | Addex Therapeutics Ltd |
Withdrawal of Acceleration Request
Registration Statement on Form F-1
File No. 333-271611
Dear Mr. Campbell:
Reference is made to our letter, filed as correspondence via EDGAR on May 11, 2023, in which we requested the acceleration of the effective date of the above-referenced Registration Statement for Friday, May 12, 2023, at 4:00 p.m. Eastern Time, in accordance with Rule 461 under the Securities Act of 1933, as amended. We are no longer requesting that such Registration Statement be declared effective at this time, and we hereby formally withdraw our request for acceleration of the effective date.
Very truly yours, | |
Addex Therapeutics Ltd. | |
/s/ Tim Dyer | |
Tim Dyer | |
Chief Executive Officer |
cc: | Josh Kaufman, Cooley LLP |
Marc Recht, Cooley LLP
David C. Boles, Cooley (UK) LLP
Frank Gerhard, Homburger AG